FLUOGUIDE A/S DK -1 (96X) - Total Liabilities
Based on the latest financial reports, FLUOGUIDE A/S DK -1 (96X) has total liabilities worth €33.76 Million EUR (≈ $39.47 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
FLUOGUIDE A/S DK -1 - Total Liabilities Trend (2021–2025)
This chart illustrates how FLUOGUIDE A/S DK -1's total liabilities have evolved over time, based on quarterly financial data. See working capital position of FLUOGUIDE A/S DK -1 to evaluate short-term liquidity relative to the company's equity base.
FLUOGUIDE A/S DK -1 Competitors by Total Liabilities
The table below lists competitors of FLUOGUIDE A/S DK -1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Midsummer AB (publ)
ST:MIDS
|
Sweden | Skr313.58 Million |
|
Savezone I C
KO:067830
|
Korea | ₩90.66 Billion |
|
Elron Electronic Industries Ltd
TA:ELRN
|
Israel | ILA13.15 Million |
|
XTI Aerospace, Inc.
NASDAQ:XTIA
|
USA | $50.80 Million |
|
Tirupati Forge Limited
NSE:TIRUPATIFL
|
India | Rs472.53 Million |
|
Derluks Yatirim Holding AS
IS:DERHL
|
Turkey | TL2.50 Billion |
|
Jinhui Shipping and Transportation Limited
F:J4O
|
Germany | €169.47 Million |
|
Young Bag Micro Motors Co Ltd
KQ:193250
|
Korea | ₩24.22 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down FLUOGUIDE A/S DK -1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 96X company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.62 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how FLUOGUIDE A/S DK -1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for FLUOGUIDE A/S DK -1 (2021–2025)
The table below shows the annual total liabilities of FLUOGUIDE A/S DK -1 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €33.76 Million ≈ $39.47 Million |
+535.50% |
| 2024-12-31 | €5.31 Million ≈ $6.21 Million |
-68.54% |
| 2023-12-31 | €16.89 Million ≈ $19.75 Million |
+362.46% |
| 2022-12-31 | €3.65 Million ≈ $4.27 Million |
-75.00% |
| 2021-12-31 | €14.61 Million ≈ $17.08 Million |
-- |
About FLUOGUIDE A/S DK -1
FluoGuide A/S, a clinical stage biotechnology company, develops drugs for precision cancer surgery in Denmark. The company offers FG001, an urokinase-type plasminogen activator receptor target imaging agent, which is in Phase II clinical trial for the treatment of high-grade glioma and lung, head, and neck cancer; and functions as a photosensitizer, which is in pre-clinical stage for the treatmen… Read more